ResMed Inc.
General ticker "RMD" information:
- Sector: Health Care
- Industry: Medical - Instruments & Supplies
- Capitalization: $36.6B (TTM average)
ResMed Inc. follows the US Stock Market performance with the rate: 52.8%.
Estimated limits based on current volatility of 1.2%: low 255.85$, high 262.33$
Factors to consider:
- Earnings expected soon, date: 2026-01-29 bmo
- Company included in S&P500 list
- Company pays dividends (quarterly): last record date 2025-11-13, amount 0.60$ (Y0.93%)
- Total employees count: 9980 (-1.6%) as of 2024
- US accounted for 63.6% of revenue in the fiscal year ended 2024-06-30
- Top business risk factors: Pandemic risks, Geopolitical risks, Supply chain disruptions, Security breaches, Regulatory and compliance
- Price in estimated range
- Earnings for 3 months up through Q1 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-06-30 to 2027-06-30
- 2025-06-30 to 2026-06-30 estimated range: [229.28$, 302.41$]
- 2026-06-30 to 2027-06-30 estimated range: [243.13$, 320.74$]
Financial Metrics affecting the RMD estimates:
- Negative: with PPE of 26.7 at the end of fiscal year the price was high
- Positive: Operating profit margin, % of 32.75 > 18.33
- Positive: Return on assets ratio (scaled to [-100,100]) of 14.63 > 6.04
- Positive: 0.04 < Operating cash flow per share per price, % of 4.69
- Positive: -9.48 < Industry operating profit margin (median), % of -5.05
- Positive: Inventory ratio change, % of 0.39 <= 0.82
- Positive: -0.04 < Industry operating cash flow per share per price (median), % of 1.24
Short-term RMD quotes
Relationship graph
Long-term RMD plot with estimates
Financial data
| YTD | 2023-06-30 | 2024-06-30 | 2025-06-30 |
|---|---|---|---|
| Operating Revenue | $4,222.99MM | $4,685.30MM | $5,146.33MM |
| Operating Expenses | $3,091.12MM | $3,365.40MM | $3,460.96MM |
| Operating Income | $1,131.87MM | $1,319.89MM | $1,685.36MM |
| Non-Operating Income | $-30.21MM | $-55.09MM | $-7.80MM |
| Interest Expense | $47.38MM | $45.71MM | $12.61MM |
| R&D Expense | $287.64MM | $307.52MM | $331.28MM |
| Income(Loss) | $1,101.66MM | $1,264.80MM | $1,677.57MM |
| Taxes | $204.11MM | $243.85MM | $276.84MM |
| Profit(Loss)* | $897.56MM | $1,020.95MM | $1,400.72MM |
| Stockholders Equity | $4,129.90MM | $4,864.04MM | $5,967.86MM |
| Inventory | $998.01MM | $822.25MM | $927.71MM |
| Assets | $6,751.71MM | $6,872.39MM | $8,174.39MM |
| Operating Cash Flow | $693.30MM | $1,401.26MM | $1,751.59MM |
| Capital expenditure | $134.00MM | $114.86MM | $89.86MM |
| Investing Cash Flow | $-1,159.85MM | $-269.78MM | $-200.04MM |
| Financing Cash Flow | $422.87MM | $-1,119.29MM | $-606.25MM |
| Earnings Per Share** | $6.12 | $6.94 | $9.55 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.